Nabi 4600001
Latest Information Update: 22 Feb 2008
At a glance
- Originator Nabi Biopharmaceuticals
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 23 May 2006 No development reported - Preclinical for Bacterial infections in Uganda (unspecified route)
- 22 Mar 2002 Nabi is now called Nabi Biopharmaceuticals
- 05 Dec 2001 The compound is still in active development